2025-12-04 - Analysis Report
Here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the provided data.

**0. Report in English**

**1. Return Rate Comparison**

*   **Ticker:** TDOC
*   **Company Overview:** Teladoc Health Inc. is a telehealth company offering virtual medical care.
*   **TDOC Cumulative Return:** -63.44%
*   **S&P 500 (VOO) Cumulative Return:** 101.61%
*   **Divergence:** -165.9 (Relative Divergence: 0.1)

**Analysis:** TDOC has significantly underperformed the S&P 500. The divergence of -165.9 indicates a substantial difference in cumulative returns. The relative divergence of 0.1 suggests that the current divergence is near its minimum value in the historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 77.0%   | 70.4%   | 51.0%   | -0.1   | 6.2    |
| 2016-2018  | 101.0%  | 69.4%   | 86.0%   | -0.1   | 8.8    |
| 2017-2019  | 141.0%  | 73.8%   | 118.0%  | 0.3    | 14.9   |
| 2018-2020  | 105.0%  | 80.9%   | 81.0%   | 0.3    | 35.5   |
| 2019-2021  | -78.0%  | 80.9%   | -125.0% | 0.3    | 16.3   |
| 2020-2022  | -252.0% | 85.9%   | -251.0% | -0.9   | 4.2    |
| 2021-2023  | -315.0% | 85.9%   | -316.0% | -1.8   | 3.8    |
| 2022-2024  | -93.0%  | 85.9%   | -113.0% | -1.9   | 1.6    |
| 2023-2025  | -34.0%  | 81.6%   | -99.0%  | -0.8   | 1.3    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate has been significantly negative in recent periods (2019-2025), indicating substantial losses for investors.
*   **MDD:** The Maximum Drawdown is consistently high, reflecting significant volatility and potential for large losses.
*   **Alpha:**  The Alpha is largely negative, showing TDOC has underperformed relative to its benchmark index in the given periods.
*   **Beta:** The Beta has fluctuated, but the negative values in more recent periods indicate an inverse correlation with the market - when the market goes up, TDOC tends to go down.
*   **Cap(B):** The market capitalization has decreased from 35.5 to 1.3.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 7.395
*   **Previous Close:** 7.5
*   **Change:** -1.4%
*   **5-day SMA:** 7.484
*   **20-day SMA:** 7.3468
*   **60-day SMA:** 8.0072

**Analysis:** The current price is below the 5-day and 60-day SMA but slightly above the 20-day SMA, suggesting a potential short-term consolidation after a recent decline. The negative change from the previous close reflects ongoing downward pressure.

**3. RSI, PPO and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 46.63
*   **PPO:** 0.953
*   **Hybrid Signal:**  cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.1 (short-term decline)
*   **Expected Return (%):** -10152.0 (Significantly negative)

**Analysis:**

*   **MRI:** The MRI of 0.9 suggests that, according to this indicator, TDOC is considered a high investment recommended.
*   **RSI:** An RSI of 46.63 is considered neutral (not overbought or oversold).
*   **PPO:** A positive PPO suggests that the short-term moving average is above the long-term moving average, indicating a potential bullish trend.
*   **Hybrid Signal:** The hybrid signal recommends buying TDOC, and considers it very safe despite the negative indicators.
*   **Recent Divergence Change:** The negative change in relative divergence indicates a short-term decline.
*   **Expected Return:** The significantly negative expected return suggests that based on current trends, long-term investment in TDOC is projected to result in substantial losses compared to the S&P 500.

**4. Recent News & Significant Events**

*   **[2025-12-03] What MACD trends signal for TDOC stock:** Suggests potential insights from MACD trends.
*   **[2025-11-08] Assessing Teladoc Health (TDOC) Valuation:**  Focuses on valuation and potential undervaluation after price weakness.
*   **[2025-11-14] Teladoc Health: Fading Hope (NYSE:TDOC):**  A pessimistic view suggesting declining prospects for the company.
*   **[2025-11-17] Insider Purchase:** A director purchased 10,000 shares, which could be a positive sign of confidence from within the company.
*   **[2025-12-03] Trend Tracker for (TDOC) (TDOC:CA):** Provides trend analysis.
*   **[2025-12-03] Is TDOC stock a momentum leader:** Analyzes TDOC's momentum.

**Analysis:** Recent news presents a mixed picture. While there are articles discussing valuation and technical indicators, the "Fading Hope" article and the significantly negative expected return paint a concerning picture. The insider purchase offers a glimmer of optimism.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (2.65)
*   **Opinions:** 21
*   **Target Price (avg/high/low):** 9.21 / 12.00 / 7.00
*   **Recent Rating Changes:** No recent rating changes were provided

**Analysis:**  Analysts, on average, have a "Hold" rating on the stock. The average target price of $9.21 suggests potential upside from the current price of $7.395, but the low target price of $7.00 suggests potential downside risk.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-30 | -0.28 | 0.63 B$    |
| 2025-07-30 | -0.19 | 0.63 B$    |
| 2025-05-01 | -0.53 | 0.63 B$    |
| 2024-10-31 | -0.19 | 0.64 B$    |
| 2025-10-30 | -0.19 | 0.64 B$    |

**Analysis:**

*   **EPS:** TDOC has reported negative Earnings Per Share (EPS) for the past five quarters.
*   **Revenue:** Revenue has remained relatively consistent. This combination suggests the company is struggling with profitability despite consistent revenue.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.63B   | 70.12%        |
| 2025-06-30 | $0.63B   | 69.85%        |
| 2025-03-31 | $0.63B   | 68.73%        |
| 2024-12-31 | $0.64B   | 70.50%        |
| 2024-09-30 | $0.64B   | 71.94%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-09-30 | $1.39B    | -3.56%   |
| 2025-06-30 | $1.42B    | -2.30%   |
| 2025-03-31 | $1.43B    | -6.52%   |
| 2024-12-31 | $1.49B    | -3.25%   |
| 2024-09-30 | $1.51B    | -2.21%   |

**Analysis:**

*   **Revenue:** Revenue is consistent but not growing significantly.
*   **Profit Margin:** Profit margins are strong, yet profitability is negative.
*   **Equity:** Equity is decreasing, indicating a decline in the company's net worth.
*   **ROE:** The negative Return on Equity (ROE) confirms that the company is not generating profits from its equity investments.

**7. Comprehensive Analysis (Summary)**

TDOC has significantly underperformed the S&P 500, with a large negative divergence in cumulative returns. Recent performance data (CAGR, Alpha) points to significant losses and underperformance relative to its benchmark. The stock price is showing potential for short-term consolidation, and the recent divergence change indicates a short-term decline. Analyst ratings are neutral. Earnings reports reveal consistent revenue but persistent losses, confirmed by negative EPS and ROE. Equity is declining, and while the high profit margin is notable, it isn't translating to overall profitability. The "Fading Hope" news headline and extremely negative expected return raise concerns about the company's future prospects. While the MRI suggests TDOC is an investment, the expected return strongly indicates otherwise. Overall, the data paints a bearish picture for TDOC, with considerable risk and uncertain long-term prospects.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.